Targeting Epigenetic Regulators with Covalent Small-Molecule Inhibitors

Area of Science:

• Biochemistry
• Pharmacology
• Molecular Biology

Background:

• Epigenetic regulation controls gene expression, crucial for health and disease, particularly cancer.
• Epigenetic dysregulation is linked to diseases, making epigenetic regulators attractive therapeutic targets.
• Current epigenetic inhibitors face challenges like moderate selectivity, limited efficacy, and drug resistance.

Purpose of the Study:

• To review the structure-based design and characterization of covalent inhibitors targeting epigenetic regulators.
• To highlight the potential benefits of covalent inhibitors in improving selectivity and in vivo efficacy.
• To discuss challenges and opportunities for covalent small-molecule inhibitors in epigenetic drug discovery.

Main Methods:

• Comprehensive literature review on structure-based design of covalent inhibitors.
• Analysis of covalent inhibitors targeting epigenetic writers, readers, and erasers.
• Discussion of in vitro and in vivo studies evaluating inhibitor performance.

Main Results:

• Covalent inhibitors demonstrate potential for enhanced selectivity across epigenetic enzyme families.
• Targeted covalent inhibition can improve in vivo efficacy compared to non-covalent counterparts.
• Structure-based design facilitates the development of potent and selective epigenetic drugs.

Conclusions:

• Covalent small-molecule inhibitors represent a promising strategy to overcome limitations in epigenetic drug development.
• Further research into targeted covalent inhibition can advance epigenetic therapies for cancer and other diseases.
• Understanding the challenges and opportunities will guide future epigenetic drug discovery efforts.